BusinessFibrocell Announces Closing of $10.5 Million Underwritten Public OfferingBy Nasdaq OMXDec 11, 2017, 9:01 PM UTC
BusinessMyriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 8, 2017, 11:00 PM UTC
BusinessNicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease ResearchBy Nasdaq OMXDec 8, 2017, 11:30 AM UTC
BusinessFibrocell Announces Pricing of $10.5 Million Underwritten Public OfferingBy Nasdaq OMXDec 7, 2017, 12:00 PM UTC
BusinessIndependent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary EndpointBy Nasdaq OMXDec 7, 2017, 11:00 AM UTC
BusinessMyriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 6, 2017, 11:00 PM UTC
BusinessUPDATE: Rich Pharmaceuticals Retains Experienced Contract Research Organization to Assist with Clinical TrialsBy Nasdaq OMXDec 5, 2017, 5:35 PM UTC
